{"id":987635,"date":"2026-07-30T20:02:49","date_gmt":"2026-07-31T00:02:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-second-quarter-financial-results-on-august-6-2026\/"},"modified":"2026-07-30T20:02:49","modified_gmt":"2026-07-31T00:02:49","slug":"cellectis-to-report-second-quarter-financial-results-on-august-6-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-second-quarter-financial-results-on-august-6-2026\/","title":{"rendered":"Cellectis to Report Second Quarter Financial Results on August 6, 2026"},"content":{"rendered":"
\n

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.<\/p>\n

The press release will be available in the Investors section of Cellectis\u2019 website: https:\/\/www.cellectis.com\/en\/investors\/press-releases\/<\/strong><\/a><\/p>\n

Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com<\/strong><\/a><\/p>\n

\n About\u202fCellectis<\/strong>\n <\/p>\n

Cellectis\u202fis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u202futilizes\u202fan allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and\u202fready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities,\u202fCellectis\u202fis one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.<\/p>\n

Cellectis\u2019 headquarters are in Paris, France, with locations in New York and Raleigh, NC.\u202fCellectis\u202fis listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit\u202fwww.cellectis.com<\/a>\u202fand follow\u202fCellectis\u202fon\u202fLinkedIn<\/a>\u202fand\u202fX<\/a>.<\/p>\n

\n For further information on\u202fCellectis, please contact:<\/strong>\n <\/p>\n

\n Media contacts:<\/strong>
\n
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,\u202fmedia@cellectis.com<\/a>
Patricia Sosa Navarro, Chief of Staff to the CEO,\u202f+33 (0)7 76 77 46 93<\/p>\n

\n Investor Relations contact:<\/strong>
\n
Arthur Stril, Chief Financial Officer & Chief Business Officer,\u202finvestors@cellectis.com<\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n